Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Phase 2 Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIRTM Protein, In Combination With Bendamustine Vs Bendamustine Alone In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)
Blood (2013)
  • Andrzej Hellman, Gdańsk Medical University
  • Janusz Kloczko, Medical University of Białystok
  • Javier Loscertales, Harvard University
  • Ewa Lech-Maranda, Medical University of Łódź
  • John M. Pagel, Fred Hutchinson Cancer Research Center
  • Anthony Mato, Hackensack University Medical Center
  • John C. Byrd, Ohio State University
  • Farrukh T Awan, Georgia Regents University
  • Holger Hebart, University of Tübingen
  • Jose A Garcia-Marco, Autonomous University of Madrid
  • Brian T. Hill, Cancer Institute
  • Michael Hallek, University of Bonn
  • Scott Stromatt
  • Ulrich Jaeger, Medical University of Vienna
Link
Disciplines
Publication Date
November 15, 2013
Citation Information
Andrzej Hellman, Janusz Kloczko, Javier Loscertales, Ewa Lech-Maranda, et al.. "Phase 2 Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIRTM Protein, In Combination With Bendamustine Vs Bendamustine Alone In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)" Blood Vol. 122 Iss. 21 (2013) p. 2860 - 2860
Available at: http://works.bepress.com/john-pagel/114/